You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

INCRELEX Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: INCRELEX
Recent Clinical Trials for INCRELEX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Children's Hospital Medical Center, CincinnatiPhase 1/Phase 2
Autism Science FoundationPhase 2
Boston Children's HospitalPhase 2

See all INCRELEX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for INCRELEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for INCRELEX Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for INCRELEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: Increlex

Introduction to Increlex

Increlex, also known as mecasermin injection, is a biologic product designed to treat severe primary insulin-like growth factor 1 deficiency (SPIGFD) in children and adolescents aged 2 to 18 years. This condition arises when the body does not produce enough insulin-like growth factor 1 (IGF-1), a critical hormone for growth and development[1][4][5].

Market Approval and Reach

Increlex is approved in 40 territories, including the United States and the European Union, and is the only treatment approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for SPIGFD. This exclusive approval position gives Increlex a significant market advantage in treating this rare condition[1][4][5].

Patient Population and Prevalence

The patient population for Increlex is relatively small but critical. It is estimated that around 200 patients in the United States and 900-1,000 patients in Europe live with SPIGFD. Despite the small patient base, the drug's importance in treating this ultra-rare condition cannot be overstated[1][4].

Acquisition by Eton Pharmaceuticals

In October 2024, Eton Pharmaceuticals announced an asset purchase agreement to acquire Increlex from Ipsen S.A. This acquisition aligns with Eton's mission to develop and distribute medicines for rare conditions and leverages their expertise in serving rare patient populations. The deal is expected to close near year-end 2024[1][5].

Financial Details of the Acquisition

The financial details of the acquisition were not disclosed. However, Eton plans to finance the deal using cash on hand and an expansion of their existing credit facility with SWK Holdings. Ipsen reported global sales for Increlex of €17.3 million in 2023, providing a baseline for Eton's future financial projections[1][5].

Commercialization Strategy

Following the acquisition, Eton will immediately commercialize Increlex in the U.S. without disrupting patient supply. Outside the U.S., Ipsen will continue distributing the product during a six-month transition period, ensuring continuity of care before Eton takes over commercialization[1][4][5].

Market Dynamics: Biologics Market

The biologics market, which includes drugs like Increlex, is experiencing significant growth. The global biologics market size is projected to reach USD 699.5 billion by 2032, growing at a CAGR of 7.8% from 2024 to 2032. This growth is driven by the rising prevalence of chronic diseases, technological advancements, and the increasing adoption of biosimilars[3].

Specific Market Drivers for Increlex

  • Rare Disease Treatment: Increlex's unique position as the only FDA and EMA-approved treatment for SPIGFD ensures a stable market demand.
  • Pediatric Endocrinology: Eton's strong presence in the pediatric endocrinology community will help in raising awareness and treating this underdiagnosed condition.
  • Global Distribution: The drug's approval in 40 territories provides a broad market reach, although the patient population is small[1][4][5].

Competitive Landscape

While Increlex operates in a niche market, the broader biologics market is highly competitive. Companies are investing heavily in research and development, and there is a strong pipeline of biologic drugs. However, Increlex's exclusivity in treating SPIGFD minimizes direct competition[3].

Regional Market Analysis

The global biologics market, including Increlex, is analyzed across regions such as North America, Europe, Asia-Pacific, and LAMEA. North America currently dominates the market due to its well-developed healthcare infrastructure and significant prevalence of chronic diseases. However, the Asia-Pacific region is anticipated to be the fastest-growing segment due to rising healthcare expenditure and developing healthcare infrastructure[2][3].

Future Growth Prospects

Given the exclusive approval and the critical nature of the condition it treats, Increlex is poised for stable growth. Eton's strategy to raise awareness of SPIGFD and their strong presence in pediatric endocrinology will likely increase the drug's market penetration. Additionally, the overall growth of the biologics market will contribute to Increlex's financial trajectory[1][4][5].

Challenges and Opportunities

  • Awareness and Diagnosis: One of the key challenges is the underdiagnosis and undertreatment of SPIGFD. Eton's efforts to raise awareness will be crucial.
  • Regulatory Environment: Continuous regulatory approvals and compliance will be essential for maintaining market position.
  • Financial Investment: The expansion of Eton's credit facility and use of cash on hand indicate a commitment to investing in the drug's commercialization and patient care[1][4][5].

Key Takeaways

  • Exclusive Approval: Increlex is the only FDA and EMA-approved treatment for SPIGFD.
  • Acquisition and Commercialization: Eton Pharmaceuticals is acquiring Increlex from Ipsen, ensuring continuity of care and long-term supply.
  • Financial Projections: The deal is financed by Eton’s cash on hand and an expansion of their credit facility, with global sales of €17.3 million in 2023 as a baseline.
  • Market Growth: The biologics market, including Increlex, is expected to grow significantly, driven by chronic disease prevalence and technological advancements.

FAQs

Q: What is Increlex used to treat? A: Increlex is used to treat severe primary insulin-like growth factor 1 deficiency (SPIGFD) in children and adolescents aged 2 to 18 years.

Q: Who is acquiring Increlex? A: Eton Pharmaceuticals is acquiring Increlex from Ipsen S.A.

Q: How will the acquisition be financed? A: The acquisition will be financed by Eton’s cash on hand and an expansion of their existing credit facility with SWK Holdings.

Q: What is the current market size of Increlex? A: Ipsen reported global sales for Increlex of €17.3 million in 2023.

Q: What are the future growth prospects for Increlex? A: Increlex is poised for stable growth due to its exclusive approval, Eton's strong presence in pediatric endocrinology, and the overall growth of the biologics market.

Citation Highlight

"Eton's mission is to develop and distribute medicines that make a life changing impact for patients with the rarest of conditions. Increlex, a critical medication for patients with the ultra-rare condition of severe IGF-1 deficiency, aligns perfectly with our mission and our significant expertise in serving extremely rare patient populations," said Sean Brynjelsen, CEO of Eton Pharmaceuticals[5].

Sources:

  1. Nasdaq: Eton Pharma To Buy SPIGFD Drug Increlex From Ipsen.
  2. Allied Market Research: Incretin-Based Drugs Market Statistics, Forecast - 2032.
  3. BioSpace: Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems.
  4. Eton Pharmaceuticals: Form 8-K for Eton Pharmaceuticals INC filed 10/03/2024.
  5. BioSpace: Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.